VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treatingpost-operative inflammation following cataract surgeryStatistically and clinically meaningful
View detailsTEL AVIV, Israel and SHANGHAI, Jan. 6, 2023 -- VivaVision, a pharmaceutical company developing innovative therapies for ocular diseases, and Everads Therapy, a biotech company developing optimized retinal therapies by leveraging its novel suprachoroidal
View detailsVivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator,
View detailsVVN001 demonstrating clinical and statistical superiority over vehicle in reducing total and sub-regional Corneal Fluorescein Staining scores
View detailsVivaVision Biotech undertook its Series C funding round, hoping to create a blockbuster drug for the treatment of ‘dry eye syndrome. --By Fan Zhang ( EqualOcean )
View details
Address ：Room 4020, Building B, Gene Medicine Valley North District, Ouhai District, Wenzhou City, Zhejiang Province
Mailbox：support@vivavisionbio.com
Copyright2020 VivaVision Biotech, Limited.
Record No ：Huicp no.18035530
